




FIG. 2







Inventor: KANDA et al. SN 09/971,773/Sheet 3 of 52 Atty. Dkt.: 249-202


FIG. 3





Inventor: KANDA et al. SN 09/971,773/Sheet 4 of 52 Atty. Dkt.: 249-202





Inventor: KANDA et al. SN 09/971,773/Sheet 5 of 52 Atty. Dkt.: 249-202

FIG. 5






FIG. 6





Inventor: KANDA et al. SN 09/971,773/Sheet 8 of 52 Atty. Dkt.: 249-202

FIG. 8A






FIG. 8B




Inventor: KANDA et al. SN 09/971,773/Sheet 9 of 52 Atty. Dkt.: 249-202

FIG. 9



Inventor: KANDA et al. SN 09/971,773/Sheet 10 of 52 Atty. Dkt.: 249-202




100 8 38.07 40.43 42.05 43.34 44.41 46.77 47.99 49.58 9 4 20 13.71 12.67 7.62 7.62 4.87 3.31 2.75 **INTENSITY LLUORESCENCE SELATIVE** 100 FIG. 11A 40 1.61 12.28 13.27 2

Inventor: KANDA et al. SN 09/971,773/Sheet 11 of 52 Atty. Dkt.: 249-202

RELATIVE INTENSITY

Inventor: KANDA et al. SN 09/971,773/Sheet 12 of 52 Atty. Dkt.: 249-202










FIG. 14





Inventor: KANDA et al. SN 09/971,773/Sheet 16 of 52 Atty. Dkt.: 249-202






--- ANTI-CCR4 CHIMERIC ANTIBODY (39%) → ANTI-CCR4 CHIMERIC ANTIBODY (27%) → ANTI-CCR4 CHIMERIC ANTIBODY (18%) --- ANTI-CCR4 CHIMERIC ANTIBODY (46%) ANTI-CCR4 CHIMERIC ANTIBODY (8%) -- ANTI-CCR4 CHIMERIC ANTIBODY (9%) ANTIBODY CONCENTRATION (µg/ml) 0.01 0.001 2.5 0.5 رن. BINDING ACTIVITY (OD415)

Inventor: KANDA et al. SN 09/971,773/Sheet 18 of 52 Atty. Dkt.: 249-202

FIG. 18



Inventor: KANDA et al. SN 09/971,773/Sheet 19 of 52 Atty. Dkt.: 249-202

FIG. 19






FIG. 20




Inventor: KANDA et al. SN 09/971,773/Sheet 21 of 52 Atty. Dkt.: 249-202

FIG. 21




Inventor: KANDA et al. SN 09/971,773/Sheet 22 of 52 Atty. Dkt.: 249-202

FIG. 22




22/52

FIG. 23



Inventor: KANDA et al. SN 09/971,773/Sheet 24 of 52 Atty. Dkt.: 249-202

FIG. 24



Inventor: KANDA et al. SN 09/971,773/Sheet 25 of 52 Atty. Dkt.: 249-202

FIG. 25






FIG. 26



Inventor: KANDA et al. SN 09/971,773/Sheet 27 of 52 Atty. Dkt.: 249-202


FIG. 27



27/52


Inventor: KANDA et al. SN 09/971,773/Sheet 28 of 52 Atty. Dkt.: 249-202

FIG. 28




Inventor: KANDA et al. SN 09/971,773/Sheet 29 of 52 Atty. Dkt.: 249-202

FIG. 29



ANTI-GD3 ANTIBODY CONCENTRATION (µg/ml)



Inventor: KANDA et al. SN 09/971,773/Sheet 31 of 52 Atty. Dkt.: 249-202




FIG. 32




FIG. 33




FIG. 34




FIG. 35




FIG. 36




FIG. 37




FIG. 38




FIG. 39




FIG. 40






FIG. 41



Inventor: KANDA et al. SN 09/971,773/Sheet 42 of 52 Atty. Dkt.: 249-202

FIG. 42



Inventor: KANDA et al. SN 09/971,773/Sheet 43 of 52 Atty. Dkt.: 249-202

FIG. 43







FIG. 44




Inventor: KANDA et al. SN 09/971,773/Sheet 45 of 52 Atty. Dkt.: 249-202





Inventor: KANDA et al. SN 09/971,773/Sheet 46 of 52 Atty. Dkt.: 249-202







Inventor: KANDA et al. SN 09/971,773/Sheet 47 of 52 Atty. Dkt.: 249-202





Inventor: KANDA et al. SN 09/971,773/Sheet 48 of 52 Atty. Dkt.: 249-202





Inventor: KANDA et al. SN 09/971,773/Sheet 49 of 52 Atty. Dkt.: 249-202

→ GMD LCA CONCENTRATION (mg/ml) 0 140 120 20 9 8 90 (%) OITAR JAVIVRUS






FIG. 53

FIG. 54



Inventor: KANDA et al. SN 09/971,773/Sheet 52 of 52 Atty. Dkt.: 249-202



This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:
☐ BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
☐ LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
• ~

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.